AstraZeneca kicks off second blood cancer launch, this time for orphan drug Lumoxiti

For the second straight year, AstraZeneca is spending the fall launching a hemo-oncology drug. Lumoxiti, a treatment for the rare disease hairy cell leukemia, is rolling out to patients after a Sept. 14 FDA approval, with AZ initially targeting 10-15 high-priority clinics.